Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KarXT · 21 trials · 13 indications
The YMRS comprised of 11 items that assess the severity of manic symptoms. All items are given a severity rating, with 4 items graded from 0 to 8 (irritability, speech, thought content, and disruptive/aggressive behavior), and the remaining 7 items are graded from 0 to 4 points. The highest score obtainable on the YMRS is 60 and the higher the number the greater the number of symptoms and/or the greater their severity.
Open-label extension (OLE) Part
Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Number of participants with TEAEs leading to treatment discontinuation.
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.
The number and percentage of participants with TEAEs will be determined
Part 1
Part 1
Part 1
Part 1
Part 1
Part 1
Part 2
Part 2
Part 2
Part 2
Part 2
Part 2
Part 2
| Arm | Type | Description |
|---|---|---|
| KarXT + KarX-EC Arm | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | - |
| Administration of KarXT for Schizophrenia | EXPERIMENTAL | - |
| Administration of KarXT for Autism-related Irritability | EXPERIMENTAL | - |
| KarXT | EXPERIMENTAL | - |
| KarXT+KarX-EC | EXPERIMENTAL | - |
| KarXT + KarX-EC | ACTIVE_COMPARATOR | - |
| KarXT or Adjuvant KarXT | EXPERIMENTAL | - |
| Administration of KarXT | ACTIVE_COMPARATOR | - |
| KarXT on empty stomach and with food | EXPERIMENTAL | - |
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Part 3 | EXPERIMENTAL | - |
| Part 1a | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KarXT | DRUG | Specified dose on specified days |
| KarX-EC | DRUG | Specified dose on specified days |
| KarXT + KarX-EC Matching Placebo | DRUG | Specified dose on specified days |
| KarXT + KarX-EC Arm Matching Placebo | DRUG | Specified dose on specified days |
| KarXT Matching Placebo | OTHER | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| Lithium | DRUG | Therapeutic dose |
| Valproate | DRUG | Therapeutic dose |
| Lamotrigine | DRUG | Therapeutic dose |
| Midazolam | DRUG | Specified dose on specified days |
| Fexofenadine | DRUG | Specified dose on specified days |
| Digoxin | DRUG | Specified dose on specified days |
| Omeprazole | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a confirmed diagnosis of ASD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria, confirmed by the K-SADS-PL and must be experiencing symptoms of irritability. * Participants must have...
Top 20 of 24 competitors
KarXT is an investigational small molecule being studied for neurological conditions, including psychosis associated with Alzheimer's disease, agitation in Alzheimer's disease, and manic episodes in bipolar-I disorder. It is in Phase 3 clinical trials and is not yet approved by the FDA.
KarXT is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting multiple Phase 3 trials to evaluate the drug's safety and efficacy in Alzheimer's disease and bipolar disorder.
KarXT is in Phase 3 clinical development. It is being evaluated in several recruiting trials, including studies for psychosis associated with Alzheimer's disease, agitation in Alzheimer's disease, and manic episodes in bipolar-I disorder. KarXT remains investigational and has not received FDA approval.
KarXT is being studied in multiple Phase 3 trials, including NCT06585787 (ADEPT-4) for psychosis in Alzheimer's disease, NCT06937229 (ADAGIO-3) for agitation in Alzheimer's disease, NCT06947941 (ADEPT-5) for psychosis in Alzheimer's disease, and NCT06951711 (BALSAM-2) for manic episodes in bipolar-I disorder.
Yes, KarXT is being studied in Alzheimer's disease. Three Phase 3 trials are recruiting patients with Alzheimer's disease: ADEPT-4 and ADEPT-5 for psychosis associated with Alzheimer's disease, and ADAGIO-3 for agitation in Alzheimer's disease. These trials are enrolling adults aged 55 years and older.
Yes, KarXT is being studied in bipolar disorder. The Phase 3 trial NCT06951711, known as BALSAM-2, is evaluating KarXT for the treatment of manic episodes in bipolar-I disorder. This trial is recruiting adults aged 18 years and older with bipolar disorder type I with mania or mania with mixed features.